Monitor FDA review milestones and any advisory committee meetings ahead of the April 2027 PDUFA date. The stock may re-rate on positive review updates or if competitor developments (e.g., Takeda's TAK-994) emerge. Near-term, the acceptance removes a key binary risk but approval remains the primary catalyst.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this press release- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 6 $33.22entry
- T+1 · 4mo ago +4.12%α +4.60% · $34.59
- T+5 · 4mo ago +5.57%α +5.08% · $35.07
- T+20 · 4mo ago −1.81%α −1.24% · $32.62
- T+60 · 7w ago −4.49%α −6.39% · $31.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris announced FDA acceptance of its New Drug Application (NDA) for deucrictibant immediate-release capsules for on-demand treatment of hereditary angioedema (HAE) attacks, with a PDUFA target action date of April 23, 2027. The NDA includes positive Phase 3 data (RAPIDe-3) showing rapid symptom relief and a well-tolerated safety profile. This milestone reduces regulatory uncertainty and positions deucrictibant as a potential first oral therapy for acute HAE attacks, though approval is still pending.
Key Facts
- FDA accepted NDA for deucrictibant IR (20 mg) for on-demand treatment of HAE attacks
- PDUFA target action date set for April 23, 2027
- Phase 3 RAPIDe-3 study met primary and all 11 secondary endpoints with statistical significance
- Median time to onset of symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours
- Deucrictibant granted orphan drug designation by FDA in 2022
Financial Impact
Not directly quantified; potential for significant revenue if approved as first oral on-demand HAE therapy, but commercial launch is contingent on FDA approval and market adoption
Risk Factors
- FDA may issue a Complete Response Letter (CRL) citing safety, efficacy, or manufacturing concerns
- Competition from existing injectable therapies (e.g., icatibant, ecallantide) and potential oral entrants
- Commercial execution risk if approved, given need to build sales infrastructure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3322293 |
Track record
51 reports on PHVS
14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers